Liposomes as drug delivery systems for the treatment of TB.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Nanomedicine

• Publication date

  2011-10-25

• Fields of study

  Medicine, Materials Science

• Identifiers
  DOI 10.2217/nnm.11.122PMID 22026379
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synthesis and biological evaluation of sugar-derived chiral nitroimidazoles as potential antimycobacterial agents.

  2011cited by this paper
• Design, synthesis and antimycobacterial evaluation of novel 3-substituted-N-aryl-6,7-dimethoxy-3a,4-dihydro-3H-indeno[1,2-c]pyrazole-2-carboxamide analogues.

  2011cited by this paper
• Advent of Imidazo[1,2-a]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis Activity.

  2011cited by this paper
• Nanocarriers for pulmonary administration of peptides and therapeutic proteins.

  2011cited by this paper
• Design and synthesis of novel cell wall inhibitors of Mycobacterium tuberculosis GlmM and GlmU.

  2011cited by this paper
• Synthesis and antitubercular evaluation of novel dibenzo[b,d]furan and 9-methyl-9H-carbazole derived hexahydro-2H-pyrano[3,2-c]quinolines via Povarov reaction.

  2011cited by this paper
• Tuberculosis drugs: new candidates and how to find more.

  2011cited by this paper
• [R207910 (TMC207): a new antibiotic for the treatment of tuberculosis].

  2010cited by this paper
• Tuberculosis drug development: progress, challenges, and the road ahead.

  2010cited by this paper
• Current development and future prospects in chemotherapy of tuberculosis

  2010cited by this paper
• Novel vaccines against tuberculosis.

  2010cited by this paper
• New Antituberculous Drugs in Development

  2010cited by this paper
• New and improved tuberculosis diagnostics: evidence, policy, practice, and impact

  2010cited by this paper
• Current pharmaceutical design of antituberculosis drugs: future perspectives.

  2010cited by this paper
• The mechanisms and consequences of the extra-pulmonary dissemination of Mycobacterium tuberculosis.

  2010cited by this paper
• Development of new anti-tuberculosis drug candidates.

  2010cited by this paper
• Recent advances in the design and synthesis of heterocycles as anti-tubercular agents.

  2010cited by this paper
• Micro- and nanocarrier-mediated lung targeting

  2010cited by this paper
• Factors affecting drug release from liposomes.

  2010cited by this paper
• New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery.

  2010cited by this paper
• The chemical biology of new drugs in the development for tuberculosis.

  2010cited by this paper
• Development of nanoparticles for antimicrobial drug delivery.

  2010cited by this paper
• New drugs and regimens for treatment of TB

  2010cited by this paper
• Production of TNF-α, IL-12(p40) and IL-17 Can Discriminate between Active TB Disease and Latent Infection in a West African Cohort

  2010cited by this paper
• Delivery of antibiotics to the respiratory tract: an update

  2009cited by this paper
• Treatment of Active Pulmonary Tuberculosis in Adults: Current Standards and Recent Advances

  2009cited by this paper
• Ultrasound, liposomes, and drug delivery: principles for using ultrasound to control the release of drugs from liposomes.

  2009cited by this paper
• On the nature of biomaterials.

  2009cited by this paper
• The Past and Future of Tuberculosis Research

  2009cited by this paper
• Who benefits from granulomas, mycobacteria or host?

  2009cited by this paper
• Novel applications of nanotechnology in medicine.

  2009cited by this paper
• Synthesis and evaluation of rifabutin analogs against Mycobacterium avium and H(37)Rv, MDR and NRP Mycobacterium tuberculosis.

  2009cited by this paper
• Lipid nanocapsules: a new platform for nanomedicine.

  2009cited by this paper
• Liposome-based cationic adjuvant formulations (CAF): Past, present, and future

  2009cited by this paper
• Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer.

  2009cited by this paper
• Effect of surface-mannose modification on aerosolized liposomal delivery to alveolar macrophages

  2009cited by this paper
• Novel Generation Mycobacterial Adjuvant Based on Liposome-Encapsulated Monomycoloyl Glycerol from Mycobacterium bovis Bacillus Calmette-Guérin1

  2009cited by this paper
• Do Nanomedicines Require Novel Safety Assessments to Ensure their Safety for Long-Term Human Use?

  2009cited by this paper
• Evaluation of antitubercular drug-loaded surfactants as inhalable drug-delivery systems for pulmonary tuberculosis.

  2009cited by this paper
• Efficient targeting to alveolar macrophages by intratracheal administration of mannosylated liposomes in rats.

  2008cited by this paper
• Mycobacterium tuberculosis and the macrophage: maintaining a balance.

  2008cited by this paper
• Nanomedicine: Application of Nanobiotechnology in Medical Practice

  2008cited by this paper
• Foamy Macrophages from Tuberculous Patients' Granulomas Constitute a Nutrient-Rich Reservoir for M. tuberculosis Persistence

  2008cited by this paper
• Mannose-targeted systems for the delivery of therapeutics

  2008cited by this paper
• Targeted delivery of nanoparticles for the treatment of lung diseases.

  2008cited by this paper
• Multifunctional nanoparticles--properties and prospects for their use in human medicine.

  2008cited by this paper
• A novel application of affinity biosensor technology to detect antibodies to mycolic acid in tuberculosis patients.

  2008cited by this paper
• Emerging nanopharmaceuticals.

  2008cited by this paper
• Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis.

  2008cited by this paper
• Ethics in nanomedicine.

  2007cited by this paper
• Optimizing efficacy of Amphotericin B through nanomodification

  2007cited by this paper
• Targeted drug delivery to enhance efficacy and shorten treatment duration in disseminated Mycobacterium avium infection in mice.

  2007cited by this paper
• Liposome-based drug delivery to alveolar macrophages

  2007cited by this paper
• Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis.

  2007cited by this paper
• Nanoparticles: pharmacological and toxicological significance

  2007cited by this paper
• Mycobacterial glycolipid trehalose 6,6'-dimycolate-induced hypersensitive granulomas: contribution of CD4+ lymphocytes.

  2007cited by this paper
• Liposomes for drug delivery to the lungs by nebulization.

  2007cited by this paper
• Interactions of pathogenic mycobacteria with host macrophages.

  2007cited by this paper
• Nanoparticles: Characteristics, Mechanisms of Action, and Toxicity in Pulmonary Drug Delivery—A Review

  2007cited by this paper
• Liposomal Drug Delivery

  2007cited by this paper
• RUTI: a new chance to shorten the treatment of latent tuberculosis infection.

  2006cited by this paper
• Nanomedicine: developing smarter therapeutic and diagnostic modalities.

  2006cited by this paper
• Nanomedicine for respiratory diseases.

  2006cited by this paper
• [Origin and development of RUTI, a new therapeutic vaccine against Mycobacterium tuberculosis infection].

  2006cited by this paper
• [Novel vaccines against M. tuberculosis].

  2006cited by this paper
• Tuberculosis: back on the immunologists' agenda.

  2006cited by this paper
• Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential

  2006cited by this paper
• New-concept chemotherapy by nanoparticles of biodegradable polymers: where are we now?

  2006cited by this paper
• Origen y desarrollo de RUTI, una nueva vacuna terapéutica contra la infección por Mycobacterium tuberculosis☆

  2006cited by this paper
• Nanotechnology based drug delivery system(s) for the management of tuberculosis.

  2006cited by this paper
• Antitubercular inhaled therapy: opportunities, progress and challenges.

  2005cited by this paper
• Lipid vesicles in capillary electrophoretic techniques: Characterization of structural properties and associated membrane‐molecule interactions

  2005cited by this paper
• Role of nanotechnology in targeted drug delivery and imaging: a concise review.

  2005cited by this paper
• Glycolipids of Mycobacterium tuberculosis Strain H37Rv Are Potential Serological Markers for Diagnosis of Active Tuberculosis

  2005cited by this paper
• Nanomedicine: current status and future prospects

  2005cited by this paper
• The Mycobacterium tuberculosis cell wall component mycolic acid elicits pathogen‐associated host innate immune responses

  2005cited by this paper
• Preparation and characterization of liposomes encapsulating chitosan nanoparticles.

  2005cited by this paper
• Liposome/water lipophilicity: Methods, information content, and pharmaceutical applications

  2004cited by this paper
• Nebulization of liposome encapsulated antitubercular drugs in guinea pigs.

  2004cited by this paper
• Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages.

  2004cited by this paper
• Mycobacterial granulomas: keys to a long-lasting host-pathogen relationship.

  2004cited by this paper
• Microparticles and nanoparticles as delivery systems for DNA vaccines.

  2003cited by this paper
• Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis.

  2003cited by this paper
• Incorporation of Antibiotics in Liposomes Designed for Tuberculosis Therapy by Inhalation

  2003cited by this paper
• Interaction of rifampicin and isoniazid with large unilamellar liposomes: spectroscopic location studies.

  2003cited by this paper
• Lipossomas: a bala mágica acertou?

  2002cited by this paper
• Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes.

  2002cited by this paper
• Pharmacokinetic Considerations in the Design of Pulmonary Drug Delivery Systems for Glucocorticoids

  2001cited by this paper
• The activity of low-clearance liposomal amikacin in experimental murine tuberculosis.

  2001cited by this paper
• Developments in liposomal drug delivery systems

  2001cited by this paper
• Restraining mycobacteria: Role of granulomas in mycobacterial infections

  2000cited by this paper
• Tuftsin-bearing liposomes in treatment of macrophage-based infections.

  2000cited by this paper
• Porins in the Cell Wall of Mycobacterium tuberculosis

  1999cited by this paper
• Porins in the Cell Wall ofMycobacterium tuberculosis

  1999cited by this paper
• Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice

  1997cited by this paper
• Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice.

  1997cited by this paper
• Nosocomial colonization and infection in persons infected with human immunodeficiency virus.

  1996cited by this paper
• Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic.

  1995cited by this paper
• [A drug delivery system and biological response modifiers for the treatment of mycobacterial infection].

  1994cited by this paper
• Tuftsin-bearing liposomes as rifampin vehicles in treatment of tuberculosis in mice

  1994cited by this paper

• Development of Co-Amorphous Systems for Inhalation Therapy—Part 2: In Silico Guided Co-Amorphous Rifampicin–Moxifloxacin and –Ethambutol Formulations

  2025cites this paper
• Nano-Liposomal Delivery Systems and their Applications in Bacterial Resistance

  2025cites this paper
• Decoding the Role of Antimicrobial Peptides in the Fight against Mycobacterium tuberculosis.

  2025cites this paper
• Current advancements in nanoparticles for vaccines and drug delivery for the treatment of tuberculosis.

  2025cites this paper
• Ultrasound-Based Micro-/Nanosystems for Biomedical Applications.

  2024cites this paper
• Recent Trends and Applications of Nanostructure-based Drug Delivery in Alleviating Chronic Obstructive Pulmonary Disease (COPD).

  2024cites this paper
• Nano vs Resistant Tuberculosis: Taking the Lung Route

  2023cites this paper
• Nanomedicines: Impactful Approaches for Targeting Pulmonary Diseases.

  2023cites this paper
• Design and in vitro assessment of chitosan nanocapsules for the pulmonary delivery of rifabutin.

  2023cites this paper
• Multi-purpose prototypes for extrapulmonary Mycobacterium tuberculosis targeting: A regenerative medicine perspective

  2023cites this paper
• Recent developments and applications of smart nanoparticles in biomedicine

  2022cites this paper
• Nanomaterials in tuberculosis DNA vaccine delivery: historical perspective and current landscape

  2022cites this paper
• Charge and rigidity effects on the encapsulation of quercetin by multilamellar vesicles

  2022cites this paper
• Emerging strategies in nanotechnology to treat respiratory tract infections: realizing current trends for future clinical perspectives

  2022cites this paper
• Nanocarrier-based approaches to combat chronic obstructive pulmonary disease.

  2022cites this paper
• Immune Repertoire and Advancements in Nanotherapeutics for the Impediment of Severe Steroid Resistant Asthma (SSR)

  2022cites this paper
• Nanostructures for drug delivery in respiratory diseases therapeutics: Revision of current trends and its comparative analysis

  2022cites this paper
• New Perspectives in Drug Delivery Systems for the Treatment of Tuberculosis.

  2021cites this paper
• Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates: In Vivo Virulence Assessment in Galleria mellonella and Potential Therapeutics by Polycationic Oligoethyleneimine

  2021cites this paper
• Physicochemical Characterization of Hyaluronic Acid and Chitosan Liposome Coatings

  2021cites this paper
• Smart Nanoparticles in Biomedicine: An Overview of Recent Developments and Applications

  2021cites this paper
• Comparison of the Efficacy of Two Novel Antitubercular Agents in Free and Liposome-Encapsulated Formulations

  2021influential citation
• Nanobiosystems for Antimicrobial Drug-Resistant Infections

  2021cites this paper
• Nano-based drug delivery systems used as vehicles to enhance polyphenols therapeutic effect for diabetes mellitus treatment.

  2021cites this paper
• Nanoparticulate Carriers—Versatile Delivery Systems

  2021cites this paper
• Polyphenols against Infectious Diseases: Controlled Release Nano-formulations.

  2021cites this paper
• Nanomedicine and Its Applications in Combating Resistance Relating to Opportunistic Pathogens With Special Reference to Tuberculosis

  2021cites this paper
• Nano-Drug Delivery Systems: Possible End to the Rising Threats of Tuberculosis.

  2021cites this paper
• Current views in chronic obstructive pulmonary disease pathogenesis and management

  2021cites this paper
• Nanopharmaceuticals to target antifilarials: Administration of old age drugs in a novel way

  2021cites this paper
• Efficacy of Combined Rifampicin Formulations Delivered by the Pulmonary Route to Treat Tuberculosis in the Guinea Pig Model

  2021cites this paper
• Antituberculosis Targeted Drug Delivery as a Potential Future Treatment Approach

  2021cites this paper
• Targeted Drug Delivery Using Tuftsin-bearing Liposomes: Implications in the treatment of infectious diseases and tumors.

  2020cites this paper
• Embedment of liposomes into chitosan physical hydrogel for the delayed release of antibiotics or anaesthetics, and its first ESEM characterization.

  2020cites this paper
• Integrative Nanomedicine for New Therapies

  2020influential citation
• Nanomedicines in Tuberculosis: Diagnosis, Therapy and Nanodrug Delivery

  2020cites this paper
• Liposomes and phytosomes for phytoconstituents

  2020cites this paper
• Engineering materials

  2020cites this paper
• Mannose receptor targeted bioadhesive chitosan nanoparticles of clofazimine for effective therapy of tuberculosis

  2020cites this paper
• Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review

  2020cites this paper
• Recent advances in ultrasound-triggered drug delivery through lipid-based nanomaterials.

  2020cites this paper
• Multidirectional Benefits of Nanotechnology in the Diagnosis, Treatment and Prevention of Tuberculosis

  2020cites this paper
• EFFECT OF SILICA NANOCONFINEMENT OF LIPID BILAYERS ON ITS PHASE TRANSITION AND ON THE COLLOIDAL STABILITY OF SILICA NANOPARTICLES

  2020cites this paper
• REVIEW ON : TARGETED DRUG DELIVERY 1 )

  2020cites this paper
• Liposome as a drug delivery system: in nano bio electronics

  2020cites this paper
• Preclinical Evidence of Nanomedicine Formulation to Target Mycobacterium tuberculosis at Its Bone Marrow Niche

  2020cites this paper
• Lipopolysaccharide Polyelectrolyte Complex for Oral Delivery of an Anti-tubercular Drug

  2019cites this paper
• Ultrasound-based drug delivery systems

  2019cites this paper
• The Increase of Anti-tuberculosis Efficacy of Rifampicin Incorporated Into Phospholipid Nanoparticles with Sodium Oleate

  2019cites this paper
• Scavenger Receptor and Targeting Strategies

  2019cites this paper
• Targeted Delivery of Antibiotics Using Microparticles to Combat Multidrug-Resistant Tuberculosis

  2019cites this paper
• Accessing lipophilicity of drugs with biomimetic models: A comparative study using liposomes and micelles

  2018cites this paper
• [Increase of antituberculosis efficiency of rifampicin embedded into phospholipid nanoparticles with sodium oleate].

  2018cites this paper
• Alternative Pharmaceutical Formulation for Oral Administration of Rifampicin

  2018cites this paper
• Establishment of a three-dimensional in vitro model of air-blood barrier to assess the translocation of nanoparticles targeted to the lung

  2018cites this paper
• Spectroscopic Studies as a Toolbox for Biophysical and Chemical Characterization of Lipid-Based Nanotherapeutics

  2018cites this paper
• Carriers for the targeted delivery of aerosolized macromolecules for pulmonary pathologies

  2018cites this paper
• The development and evaluation of a novel hybrid PLGA nanoparticle-Pheroid® with the potential to improve tuberculosis therapy

  2018influential citation
• Mucoadhesive chitosan-coated solid lipid nanoparticles for better management of tuberculosis.

  2018cites this paper
• Nanoformulations for the Therapy of Pulmonary Infections

  2017cites this paper
• Targeted Drug Delivery System : Current and Novel Approach

  2017cites this paper
• Targeted macrophages delivery of rifampicin-loaded lipid nanoparticles to improve tuberculosis treatment.

  2017cites this paper
• Gelatinized-core liposomes: Toward a more robust carrier for hydrophilic molecules.

  2017cites this paper
• Oral Administration of Nanoparticles-Based TB Drugs

  2017cites this paper
• Liposomes as potential nanocarriers for theranostic applications in chronic inflammatory lung diseases

  2017cites this paper
• Fusion of a New World Alphavirus with Membrane Microdomains Involving Partially Reversible Conformational Changes in the Viral Spike Proteins.

  2017cites this paper
• Formulation of 99mTechnetium-labeled leuprolide loaded liposomes and its biodistribution study in New Zealand white female rabbits for assessment of its uterine targeting efficiency

  2017cites this paper
• Liposomal and Phytosomal Formulations

  2016cites this paper
• Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis

  2016influential citation
• The formulation of nanomedicines for treating tuberculosis.

  2016cites this paper
• Combating Tuberculosis Infection: A Forbidding Challenge

  2016cites this paper
• Rational design of liposomal drug delivery systems, a review: Combined experimental and computational studies of lipid membranes, liposomes and their PEGylation.

  2016cites this paper
• Nitric oxide in paediatric respiratory disorders: novel interventions to address associated vascular phenomena?

  2016cites this paper
• A New Era of Pulmonary Delivery of Nano-antimicrobial Therapeutics to Treat Chronic Pulmonary Infections.

  2016cites this paper
• Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape

  2016cites this paper
• Nanoliposome-based antibacterial drug delivery

  2015influential citation
• LIPOSOME: A POWERFUL APPROACH FOR VESICULAR DRUG DELIVERY SYSTEM

  2015cites this paper
• Liposome as efficient system for intracellular delivery of bioactive molecules

  2015cites this paper
• Synthetic Nanoparticles for Vaccines and Immunotherapy.

  2015cites this paper
• The use of ultrasound to release chemotherapeutic drugs from micelles and liposomes

  2015cites this paper
• Stimuli-responsive liposomes for the delivery of nucleic acid therapeutics.

  2015cites this paper
• Novel targeting of PEGylated liposomes for codelivery of TGF-β1 siRNA and four antitubercular drugs to human macrophages for the treatment of mycobacterial infection: a quantitative proteomic study

  2015cites this paper
• Dynamics of Chemotherapeutic Drug Release from Liposomes Using Low-Frequency Ultrasound

  2015cites this paper
• The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells

  2014cites this paper
• Interactions of isoniazid with membrane models: implications for drug mechanism of action.

  2014cites this paper
• Formation of nanocarrier systems by dense gas processing.

  2014cites this paper
• Nanocarriers for respiratory diseases treatment: recent advances and current challenges.

  2014cites this paper
• Fabrication of polyelectrolyte multilayered vesicles as inhalable dry powder for lung administration of rifampicin.

  2014cites this paper
• Interactions of N'-acetyl-rifabutin and N'-butanoyl-rifabutin with lipid bilayers: a synchrotron X-ray study.

  2013cites this paper
• The advantages of liposomes as drug carriers

  2013influential citation
• Natural carriers for application in tuberculosis treatment

  2013cites this paper
• Evaluation of the structure-activity relationship of rifabutin and analogs: a drug-membrane study.

  2013cites this paper
• Newer Anti-TB Drugs and Drug Delivery Systems

  2013cites this paper
• Lyophilization of a triply unsaturated phospholipid: effects of trace metal contaminants.

  2013cites this paper
• Isoniazid‐gelatin conjugate microparticles containing rifampicin for the treatment of tuberculosis

  2013cites this paper
• Effects of a novel antimycobacterial compound on the biophysical properties of a pulmonary surfactant model membrane.

  2013cites this paper
• Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases

  2013cites this paper
• Nanoparticles as drug delivery system for antituberculous drugs

  2013cites this paper
• Development and Characterization of Nanocarrier Systems for the Delivery of Antitubercular Drugs

  2013cites this paper
• Vesicular systems in treatment of rheumatoid arthritis

  2013cites this paper